trending Market Intelligence /marketintelligence/en/news-insights/trending/mItV0j0E5icSHrZ388OElg2 content esgSubNav
In This List

Pediapharm changes name to Medexus Pharmaceuticals

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

Blog

Investment Banking Essentials Newsletter April Edition - 2022


Pediapharm changes name to Medexus Pharmaceuticals

Pediapharm Inc. shareholders approved a change in the company's name to Medexus Pharmaceuticals Inc. on Dec. 12.

Shareholders also approved a 1-for-15 share consolidation of the company's stock which will begin trading on a post-consolidation and post-name change basis on the TSX Venture Exchange under the MDP symbol in the near future.

The company decided to change its name following its acquisitions of Medexus Inc., which is focused on rheumatology, women's health and dermatology, and Medac Pharma Inc., which sells rheumatoid arthritis therapy Rasuvo.

Canada's Medexus will operate as a specialty pharmaceutical company.